Exact Sciences Corp (EXAS) is a publicly traded Healthcare sector company. As of May 21, 2026, EXAS trades at $104.91 with a market cap of $20.03B and a P/E ratio of -95.37. EXAS moved -0.02% today. Year to date, EXAS is +56.63%; over the trailing twelve months it is +136.92%. Its 52-week range spans $38.81 to $104.98. Analyst consensus is buy with an average price target of $103.18. Rallies surfaces EXAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
EXAS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. EXAS recently traded at $104.91. Market cap is $20.03B. P/E ratio is -95.37. Revenue is $3.25B.
| Metric | Value |
|---|---|
| Price | $104.91 |
| Market Cap | $20.03B |
| P/E Ratio | -95.37 |
| EPS | $-1.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $104.98 |
| 52-Week Low | $38.81 |
| Volume | 21.56M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.25B |
| Net Income | $-207.95M |
| Gross Margin | 69.69% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.25B | $-207.95M | $-1.10 |
| 2023 | $2.50B | $-204.15M | $-1.13 |
| 2022 | $2.08B | $-623.51M | $-3.54 |
| 2021 | $1.77B | $-595.63M | $-3.48 |
41 analysts cover EXAS: 0 strong buy, 22 buy, 17 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $103.18.